Signet Healthcare Partners (“Signet”) was founded in 1998 to focus on investments in the healthcare sector. Since inception, Signet has raised four funds, with aggregate capital commitments in excess of $400 million, and has invested in more than 45 companies. These investments have generated positive returns for our investors through capital market transactions and M&A exits. Signet is currently making new investments out of its fourth fund (“Fund IV’). The Fund IV team is comprised of three senior investment professionals and a network of venture partners and operating advisors.

Throughout our history, we have remained focused on growth-stage healthcare investing. Our team of investment professionals and network of advisors have decades of experience investing in and building successful businesses across capital market cycles. It is our goal to be domain experts and strategic partners to our portfolio companies and their management teams. We maintain a disciplined yet flexible investment approach and understand the steps needed to develop growth-stage companies into leading businesses in a capital efficient manner. We have a concentrated portfolio which enables us to play an active role in building value by working closely with our companies. 

While each investment opportunity is unique, there are common elements to our approach and the criteria we apply…

Investment Characteristics

Sector Focus

We seek to be value-added partners to our portfolio companies and focus on select areas in which we have expertise. Signet’s investments have consistently been concentrated in the following market segments: 

  • Specialty pharmaceuticals (including Generics) 
  • Pharmaceutical services
  • Medical devices
  • Diagnostics

Business Profile

  • Commercial stage companies within our sector focus areas that are generating revenues or gearing up for commercial launch
  • Do not typically invest in earlier stage development companies
  • Privately held companies or structured investments in public companies
  • Business stage overlaps with late-stage venture capital and private equity
  • Primarily companies in North America and Europe but have a history investing in other geographies, usually with a local partner


Participation and Role

  • As Lead investor with experience in syndicate building when necessary 
  • Significant minority or majority equity positions
  • Active involvement including participation at the Board level
  • Typical investment of $10-15M per portfolio company
  • Ability to augment capital deployed via co-investments from our Investors

Our Value Add

Close collaboration with management teams to drive revenue growth and operating leverage via:

  • Access to our broad network of strategic partners and operators
  • Customer and potential collaboration partner introductions 
  • Supplementing management teams with talented professionals and recruiting high-caliber Board members
  • Providing strategic insights, corporate finance advice and business development assistance